Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Type 2 diabetes (T2D) patients with CKD will be eligible for the approval. The new indication makes Ozempic the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback